Document is current
Any future updates will be listed below
-
Authors
Dugan, Michelle M.
Israeli, Jacob
Olofsson Bagge, Roger
Zager, Jonathan S. https://orcid.org/0000-0002-6886-4468
- License Information
-
More Information
Article History
Received: 6 May 2025
Accepted: 6 May 2025
First Online: 26 May 2025
Disclosure
: Dr. Michelle M. Dugan and Jacob Israeli have no conflicts of interest or financial ties to disclose. Dr. Roger Olofsson Bagge has received institutional research grants from Bristol-Myers Squibb (BMS), Endomagnetics Ltd (Endomag), and SkyLineDx; speaker honorarium from Roche, Pfizer, and Pierre-Fabre; has served on advisory boards for Amgen, BD/BARD, Bristol-Myers Squibb (BMS), Merck Sharp & Dohme (MSD), Novartis, Roche, and Sanofi Genzyme; and is a shareholder in SATMEG Ventures AB. Dr. Jonathan S. Zager has received payments from Delcath Systems – Medical Advisory Board. He has received fees from Philogen, Merit Medical, Castle Biosciences, Menarini Silicon Biosystems, Replimune, and Merck. He is the owner of two US patents on high-flow isolated limb infusion. The funders had no role in the design of the study; in the collection, analyses, or interpretation of data; in the writing of the manuscript; or in the decision to publish the results.
